TNF and inflammatory bowel disease: For example, patients with IBD who achieve ’early' clinical remission at 14 weeks with anti-cytokine therapy (anti-TNF, anti-IL 12/23) have significantly higher microbial species richness at baseline compared to non-responders (65).